{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095408","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.446781+00:00","generated_at":"2026-05-31T10:05:33.854594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Erasca Q2 net loss $63.2M; cash $460M; in-licenses RAS drugs, begins Phase 3","bullets":["Net loss $63.2M ($0.29/share) vs $31.8M ($0.21/share) YOY; R&D $33M including $22.5M in-license payments.","Cash, equivalents & securities $460.2M (up from $322M Dec 2023); runway into H1 2027.","In-licensed pan-RAS glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001; IND filings H1 2025 and Q1 2025.","Initiated SEACRAFT-2 Phase 3 trial for naporafenib + trametinib in NRASm melanoma; randomized data 2025.","Phase 1b combo data in RAS Q61X tumors expected Q4 2024; initial monotherapy data for ERAS-0015/4001 in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095408","json":"https://secwatch.observer/filing/0000950170-24-095408.json","markdown":"https://secwatch.observer/filing/0000950170-24-095408.md","text":"https://secwatch.observer/filing/0000950170-24-095408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/0000950170-24-095408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024095408/eras-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:33.854594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}